Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Francini, Edoardo; Gray, Kathryn P.; Xie, Wanling; Shaw, Grace; Valença, Loana Bueno; Bernard, Brandon; Albigès, Laurence; Harshman, Lauren C.; Kantoff, Philip W.; Taplin, Mary‐Ellen; Sweeney, C.

doi:10.1002/pros.23645

Cited by 144 publications

(90 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fourth, patients with de novo mPCa showed worse time to castration and survival compared with those who relapsed after local therapy, irrespective of treatment received [ 14 , 15 ]. Therefore, the intrinsic aggressiveness of de novo mPCa could have also led to decreased survival gains in this patient population.…”

Section: Discussionmentioning

confidence: 99%

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

Cattrini

Soldato

Rubagotti

et al. 2020

Cancers

View full text Add to dashboard Cite

The real-world outcomes of patients with metastatic prostate cancer (mPCa) are largely unexplored. We investigated the trends in overall survival (OS) and cancer-specific survival (CSS) in patients with de novo mPCa according to distinct time periods. The U.S. Surveillance, Epidemiology, and End Results (SEER) Research Data (2000–2017) were analyzed using the SEER*Stat software. The Kaplan–Meier method and Cox regression were used. Patients with de novo mPCa were allocated to three cohorts based on the year of diagnosis: A (2000–2003), B (2004–2010), and C (2011–2014). The maximum follow-up was fixed to 5 years. Overall, 26,434 patients were included. Age, race, and metastatic stage (M1) significantly affected OS and CSS. After adjustment for age and race, patients in Cohort C showed a 9% reduced risk of death (hazard ratio (HR): 0.91 (95% confidence interval [CI] 0.87–0.95), p < 0.001) and an 8% reduced risk of cancer-specific death (HR: 0.92 (95% CI 0.88–0.96), p < 0.001) compared with those in Cohort A. After adjustment for age, race, and metastatic stage, patients in Cohort C showed an improvement in OS and CSS compared with Cohort B (HR: 0.94 (95% CI 0.91–0.97), p = 0.001; HR: 0.89 (95% CI 0.85–0.92), p < 0.001). Patients with M1c disease had a more pronounced improvement in OS and CSS compared with the other stages. No differences were found between Cohorts B and C. In conclusion, the real-world survival of de novo mPCa remains poor, with a median OS and CSS improvement of only 4 months in the latest years.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

Cattrini

Soldato

Rubagotti

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…The present study showed that the CHAARTED and LATITUDE risk criteria could apply to Japanese patients. Furthermore, prognoses in clinical trials including GETUG‐AFU 15, CHAARTED and LATITUDE were apparently worse than those in real‐world studies from the USA, Western Europe and Japan; whereas prognoses in the real‐world studies seem to be similar, with small differences (Table ). In particular, the difference in OS between clinical trials and the present study would be greater when age was adjusted, which might be due to differences in race and medical care for castration‐resistant prostate cancer.…”

mentioning

confidence: 97%

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

et al. 2018

View full text Add to dashboard Cite

“…The authors identified three prognostic subgroups: good prognosis for those with prior local treatment and low-volume disease; intermediate prognosis for those with prior local treatment and high-volume disease, or those with low-volume disease and de novo metastases; and poor prognosis for those with de novo high-volume disease. These data were recently confirmed by a retrospective cohort of 436 consecutive patients with mHSPC treated with ADT at the Dana-Farber Cancer Institute between 1990 and 2013 [18].…”

Section: Prognostic and Predictive Factors In Mhspcmentioning

confidence: 71%

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer

Cattrini

Castro

Lozano

et al. 2019

Cancers

View full text Add to dashboard Cite

The possible treatments options for metastatic hormone-sensitive prostate cancer (mHSPC) have dramatically increased during the last years. The old backbone, which androgen-deprivation therapy (ADT) is the exclusive approach for hormone-naïve patients, has been disrupted. Despite the fact that several high-quality, randomized, controlled phase 3 trials have been conducted in this setting, no direct comparison is currently available among the different strategies. Inadequate power, absence of preplanning and small sample size frequently affect the subgroup analyses according to disease volume or patient’s risk. The choice between ADT alone and ADT combined with docetaxel, abiraterone acetate, enzalutamide, apalutamide or radiotherapy to the primary tumor remains challenging. Factors that are related to the tumor, patient or drug side effects, currently guide these clinical decisions. This comprehensive review aims to indirectly compare the phase 3 trials in the mHSPC setting, in order to extrapolate data useful for treatment selection, providing also perspectives on future biomarkers.

show abstract

Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)

Abstract: In our hospital-based registry, time of metastatic presentation and disease volume were prognostic for mHSPC pts treated with ADT. This simple prognostic classification system can aid patient counseling and future trial design.

Cited by 144 publications

References 21 publications

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

Epidemiological Characteristics and Survival in Patients with De Novo Metastatic Prostate Cancer

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer

Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer

Contact Info

Product

Resources

About